Skip to main content

Table 2 Univariate analyses of progression and minimal clinically important difference (MCID ≥ 5)

From: Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry

Variable

Progression

Minimal clinical important difference (MCID ≥5)

B

95% CI

p

OR

95% CI

p

Strategy (monotherapy)

1.79

0.75–2.82

0.001

2.66

1.21–5.82

0.015

TJC28

−0.11

−0.20– -0.01

0.033

0.89

0.81–0.98

0.016

SJC28

0.01

−0.10–0.13

0.805

1.03

0.96–1.10

0.471

ESR

0.03

0.00–0.05

0.033

1.02

1.00–1.03

0.038

CRP

0.02

−0.00–0.04

0.084

1.01

1.00–1.02

0.071

Wellbeing

−0.01

−0.04–0.01

0.196

0.99

0.98–1.01

0.319

PCS

0.01

−0.07–0.09

0.803

1.02

0.97–1.07

0.467

MCS

−0.03

−0.09–0.04

0.408

1.01

0.97–1 .05

0.653

RF

0.09

−0.45–0.62

0.755

0.78

0.54–1.14

0.202

Anti-CCP positive

0.86

−0.23–1.95

0.123

2.41

1.04–5.57

0.040

Age

0.04

0.00–0.08

0.042

1.02

0.99–1.05

0.251

Gender

0.28

−0.82–1.38

0.621

0.75

0.36–1.56

0.443

DAS28_ESR

−0.02

−0.51–0.47

0.948

0.94

0.67–1.31

0.708

Remission 52 weeks

−0.83

−2.07–0.41

0.188

0.64

0.29–1.42

0.272

Remission 6 months

−0.73

−1.79–0.34

0.179

0.54

0.26–1.11

0.094

Remission 3 months

−0.90

−1.99–0.19

0.104

0.71

0.33–1.54

0.388

HAQ-SDI

0.62

−0.46–1.69

0.260

1.00

0.54–1.85

0.994

BMI

−0.05

−0.17–0.07

0.417

0.91

0.83–1.00

0.039

Injection triamcinolone

−1.63

−2.81– -0.46

0.007

0.39

0.15–1.07

0.067

  1. TJC tender joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PCS physical component summary, MCS Mental component summary, DAS28 Disease Activity in 28 joints, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide, HAQ-SDI Health Assessment Questionnaire disability index (standard scoring), BMI body mass index